Amgen and Kyowa Kirin's rocatinlimab showed strong efficacy in Phase 3 trials for atopic dermatitis, achieving key endpoints ...

That doesn’t mean, however, that Amgen stock is ready for a reversal. It may in fact mean that the market views AMGN as a ...

This raises an important question: Are these moves into overbought conditions a signal of potential exhaustion, suggesting ...

Data from two more late-stage studies show that treatment with Amgen's rocatinlimab improves outcomes in atopic dermatitis indication.

In September 2024, a readout from a separate trial of rocatinlimab elicited mixed reactions from analysts, who found the ...

Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in ...

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The ...

The three most widely followed U.S. indexes ended in red last week. The S&P 500, the Dow Jones Industrial Average and the ...

Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...

Research analysts at William Blair issued their Q1 2026 EPS estimates for shares of Amgen in a research note issued on ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.